GDGeoffroy Delplancq

Geoffroy Delplancq

*This is an algorithmically generated author record based on publicly available information.

Geoffroy Delplancq has a total of 197 co-authors. Here are the top co-authors by number of shared publications:

  • Paul Kuentz

    Université Marie et Louis Pasteur, CHU Besançon Franche‐Comté Oncobiologie Génétique Bioinformatique, FHU TRANSLAD Besançon France

    4 shared publications
  • Annick Toutain

    Department of Genetics, Bretonneau University Hospital, Tours, France

    2 shared publications
  • Bertrand Isidor

    Department of Genetics Nantes University Hospital Nantes France

    2 shared publications
  • Jeanne Amiel

    Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center University Paris Cité Paris France

    2 shared publications
  • Marlène Rio

    Department of Genomic Medicine of Rare Disorders, Necker Hospital, APHP Center University Paris Cité Paris France

    2 shared publications
  • Stéphanie Arpin

    Department of Genetics Tours University Hospital, UMR 1253, iBrain, University of Tours, Inserm Tours France

    2 shared publications

Latest Publications

  • Seizures in SRRM2-related disorder and treatment response

    by Daniel Fouz-Ruiz, Álvaro Beltrán-Corbellini, Bert B.A. de Vries, Lilian Bomme Ousager, Maria Iascone, Claudia Dosi, Geoffroy Delplancq, Alexander Stegmann, Tahsin Stefan Barakat, Yolande van Bever, et al.

  • Open Access

    COCH-Related Hearing Loss in a French Cohort: Novel Variants and Genotype–Phenotype Correlations

    by Ralyath Balogoun, Margaux Serey-Gaut, Véronique Pingault, Isabelle Lemiere, Geneviève Lina-Granade, Geoffroy Delplancq, Anne Marie Guerrot, Annick Toutain, Delphine Dupin-Deguine, Marine Legendre, et al.

    Objectives: To characterize heterozygous pathogenic COCH variants in a French cohort with non-syndromic sensorineural hearing loss (NSHL) and assess genotype–phenotype correlations in autosomal dominant NSHL (DFNA9). Setting: National Reference Center for Genetic Hearing Loss, Necker–Enfants Malades Hospital, Paris, France. Methods: This retrospective observational study included 69 individuals from 20 unrelated families diagnosed with DFNA9 (2005–2025). All individuals underwent clinical and audiological evaluations and genetic testing via targeted COCH Sanger sequencing or next-generation sequencing (NGS) panels. Variants were interpreted according to ACMG guidelines. Audiometric profiles and vestibular data were collected. Results: Seven known pathogenic COCH variants were found in ten families, and ten novel likely pathogenic variants in the others. Variants in vWFA domains were associated with early or late onset, progressive, bilateral and symmetrical hearing loss. Three variants (p.Gln410Arg, p.Ile450Val, p.Cys542Arg) were associated with congenital or prelingual onset, an atypical DFNA9 presentation. Variants in the LCCL domain were associated with later-onset hearing loss and more frequent vestibular dysfunction. Vestibular abnormalities were observed in about half of early-onset cases. Conclusions:COCH-related hearing loss is a rare cause of autosomal dominant NSHL, with only 20 families identified over two decades within the French network. This study expands the mutational spectrum of COCH by reporting ten novel variants and supports a domain-specific genotype–phenotype correlation. These findings improve the understanding of DFNA9 variability and have direct implications for clinical diagnosis, prognosis, and genetic counseling.

  • Open Access

    Autism Spectrum Disorder in Hypothalamic Hamartoma: Early Developmental Trajectory, Symptom Profile, and Relevance for Autism Research

    by Pierre Augé, Charlotte Mansat, Geoffroy Delplancq, Dinane Samara-Boustani, Marie-Joëlle Orêve, Mario Speranza

    Focal brain lesions occurring during critical developmental periods can shed light on the neural substrates underlying autistic symptoms. Hypothalamic hamartomas (HH) are rare congenital malformations that are typically characterized by pharmacoresistant epilepsy, endocrine disturbances, and behavioral or psychiatric disorders. Although autistic symptoms have occasionally been reported in children with HH, they remain poorly described and are rarely documented with standardized diagnostic tools. We present a case report of a 3‐year‐old boy with HH who was followed from 2 years of age. The report combines detailed early neurodevelopmental history, neuroimaging data, and standardized autism assessments. The child exhibited global developmental delay, early intense sensory features, and marked social communication deficits. The first developmental difficulties preceded the onset of seizures. At 29 months of age, magnetic resonance imaging identified a small intrahypothalamic hamartoma. At 36 months, the Autism Diagnostic Observation Schedule‐2 and the Autism Diagnostic Interview‐Revised confirmed the diagnosis of autism spectrum disorder (ASD). A comparison with 3 subjects with ASD matched for sex, chronological age, and developmental age showed that the child presented less severe deficits in sharing enjoyment and less intense unusual preoccupations than age‐matched autistic peers. This case highlights the importance of systematic ASD screening in children with HH, allowing timely referral to evidence‐based early interventions. Moreover, HH may offer a valuable framework for investigating early neurodevelopmental mechanisms associated with ASD, while highlighting the potential contribution of the hypothalamus to early autism mechanisms.

  • Open Access

    Deciphering the genetic basis of developmental language disorder in children without intellectual disability, autism or apraxia of speech

    by Clothilde Ormieres, Marion Lesieur-Sebellin, Karine Siquier-Pernet, Geoffroy Delplancq, Marlene Rio, Mélanie Parisot, Patrick Nitschké, Cristina Rodriguez-Fontenla, Alison Bodineau, Lucie Narcy, et al.

    Developmental language disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability (ID). The clinical heterogeneity of language disorders, the frequent presence of comorbidities, and the inconsistent terminology used over the years have impeded both research and clinical practice. Identifying sub-groups of children (i.e. DLD cases without childhood apraxia of speech (CAS)) with language difficulties is essential for elucidating the underlying genetic causes of this condition. DLD presents along a spectrum of severity, ranging from mild speech delays to profound disturbances in oral language structure in otherwise typically intelligent children. The prevalence of DLD is ~ 7-8% or 2% if severe forms are considered. This study aims to investigate a homogeneous cohort of DLD patients, excluding cases of ASD, ID or CAS, using multiple genomic approaches to better define the molecular basis of the disorder. Fifteen families, including 27 children with severe DLD, were enrolled. The majority of cases (n = 24) were included in multiplex families while three cases were sporadic. This resulted in a cohort of 59 individuals for whom chromosomal microarray analysis and exome or genome sequencing were performed. We identified copy number variants (CNVs) predisposing to neurodevelopmental disorders with incomplete penetrance and variable expressivity in two families. These CNVs (i.e., 15q13.3 deletion and proximal 16p11.2 duplication) are interpreted as pathogenic. In one sporadic case, a de novo pathogenic variant in the ZNF292 gene, known to be associated with ID, was detected, broadening the spectrum of this syndrome. The strict diagnostic criteria applied by our multidisciplinary team, including speech-language physicians, neuropsychologists, and paediatric neurologists, resulted in a relatively small sample size, which limit the strength of our findings. These findings highlight a common genetic architecture between DLD, ASD and ID, and underline the need for further investigation into overlapping neurodevelopmental pathways. ClinicalTrials.gov Identifier: NCT06660108.


  • Open Access

    Severe Neurodevelopmental Disorder due to Klinefelter Syndrome and CACNA1C Variant: A Case Report

    by Imen El Kamel El Lebbi, Séverine Bacrot, Myrtille Spentchian, Agnès Taillandier, Sophie Brisset, Geoffroy Delplancq

    Klinefelter syndrome (KS) is a common sex chromosome aneuploidy characterized by tall stature, hypogonadism, and learning disabilities. However, the severity of clinical presentation can vary significantly among individuals. We report a 13‐year‐old male patient adopted from Colombia who was diagnosed with KS at age 5.5 due to learning and behavioral difficulties. Despite the typical KS features, his clinical presentation was unusually severe, including significant developmental delay, behavioral issues, and physical abnormalities. Due to the uncommon severe presentation of KS in our patient, exome sequencing (ES) was performed, revealing a de novo heterozygous frameshift likely pathogenic variant in CACNA1C (c.2662del p.[Arg888Glyfs ∗ 18]). CACNA1C pathogenic variants are associated with several phenotypes, including neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures. This case emphasizes the importance of considering additional genetic investigations in KS patients with atypically severe symptoms. Such an approach can identify secondary genetic events that contribute to the phenotype, guiding a more comprehensive clinical management and allowing a more precise genetic counseling.

  • 3q29 duplications: A cohort of 46 patients and a literature review

    by Marie Massier, Martine Doco‐Fenzy, Matthieu Egloff, Xavier Le Guillou, Gwenaël Le Guyader, Sylvia Redon, Caroline Benech, Karine Le Millier, Kevin Uguen, Juliette Ropars, et al.

    Duplications of the 3q29 cytoband are rare chromosomal copy number variations (CNVs) (overlapping or recurrent ~1.6 Mb 3q29 duplications). They have been associated with highly variable neurodevelopmental disorders (NDDs) with various associated features or reported as a susceptibility factor to the development of learning disabilities and neuropsychiatric disorders. The smallest region of overlap and the phenotype of 3q29 duplications remain uncertain. We here report a French cohort of 31 families with a 3q29 duplication identified by chromosomal microarray analysis (CMA), including 14 recurrent 1.6 Mb duplications, eight overlapping duplications (>1 Mb), and nine small duplications (<1 Mb). Additional genetic findings that may be involved in the phenotype were identified in 11 patients. Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities. Although some are de novo, most of the 3q29 duplications are inherited from a parent with a similar mild phenotype. Besides, the study of small 3q29 duplications does not provide evidence for any critical region. Our data suggest that the overlapping and recurrent 3q29 duplications seem to lead to mild NDD and that a severe or syndromic clinical presentation should warrant further genetic analyses.


  • Open Access

    TELO2‐related syndrome (You‐Hoover‐Fong syndrome): Description of 14 new affected individuals and review of the literature

    by Daniah Albokhari, Amanda Barone Pritchard, Adelyn Beil, Candace Muss, Caleb Bupp, Dorothy K. Grange, Geoffroy Delplancq, Jennifer Heeley, Melissa Zuteck, Michelle M. Morrow, et al.

    You‐Hoover‐Fong syndrome (YHFS) is an autosomal recessive condition caused by pathogenic variants in the TELO2 gene. Affected individuals were reported to have global developmental delay, intellectual disability, microcephaly, dysmorphic facial features, ocular involvement including cortical visual impairment, strabismus, cataract and rotatory nystagmus, movement disorder, hypertonia and spasticity, balance disturbance and ataxia, and abnormal sleep pattern. Other features reported include poor growth, cleft palate, cardiac malformations, epilepsy, scoliosis, and hearing loss. To date, 12 individuals with YHFS have been reported in the literature. Here we describe 14 new individuals with YHFS from 10 families. Their clinical presentation provides additional support of the phenotype recognized previously and delineates the clinical spectrum associated with YHFS syndrome. In addition, we present a review of the literature including follow‐up data on four previously reported individuals with YHFS.


  • The Largest Germline Heterozygous Deletion Encompassing Potocki–Shaffer and WAGR Syndromes Loci to Date: A Case Report

    by Geoffroy Delplancq, Mohamed Abdelatif Boukebir, Daniel Amsallem, Laurent Thines, Virginie Rozé, Eric Dahlen, Lionel Van Maldergem, Paul Kuentz

    Potocki–Schaffer syndrome includes multiple exostoses, parietal foramina, and variable developmental delay/intellectual disability. It is associated with a heterozygous deletion of the 11p12p11.2 region. In some cases, the deletion extends to the WAGR locus (11p13p12). We describe here a 9-month-old girl harboring the largest germline heterozygous deletion characterized so far. Oligohydramnios and parietal foramina were noticed during pregnancy. No patient has been diagnosed before with concomitance of these two syndromes during the prenatal period. Cytogenetic diagnosis was anticipated on basis of clinical and radiological signs. Postnatal conventional karyotype confirmed an interstitial 11p deletion: 46,XX,del(11)(p11.2p15.1). Array-comparative genomic hybridization characterized a 29.6 Mb deletion. Our case illustrates the interest of high-resolution genomic approaches to correlate adequately clinical phenotypes with specific genes in suspected contiguous gene deletion syndromes.


  • Open Access

    New Insights into Potocki-Shaffer Syndrome: Report of Two Novel Cases and Literature Review

    by Slavica Trajkova, Eleonora Di Gregorio, Giovanni Battista Ferrero, Diana Carli, Lisa Pavinato, Geoffroy Delplancq, Paul Kuentz, Alfredo Brusco

    Potocki-Shaffer syndrome (PSS) is a rare non-recurrent contiguous gene deletion syndrome involving chromosome 11p11.2. Current literature implies a minimal region with haploinsufficiency of three genes, ALX4 (parietal foramina), EXT2 (multiple exostoses), and PHF21A (craniofacial anomalies, and intellectual disability). The rest of the PSS phenotype is still not associated with a specific gene. We report a systematic review of the literature and included two novel cases. Because deletions are highly variable in size, we defined three groups of patients considering the PSS-genes involved. We found 23 full PSS cases (ALX4, EXT2, and PHF21A), 14 cases with EXT2-ALX4, and three with PHF21A only. Among the latter, we describe a novel male child showing developmental delay, café-au-lait spots, liner postnatal overgrowth and West-like epileptic encephalopathy. We suggest PSS cases may have epileptic spasms early in life, and PHF21A is likely to be the causative gene. Given their subtle presentation these may be overlooked and if left untreated could lead to a severe type or deterioration in the developmental plateau. If our hypothesis is correct, a timely therapy may ameliorate PSS phenotype and improve patients’ outcomes. Our analysis also shows PHF21A is a candidate for the overgrowth phenotype.


  • Cardiomyopathy due to PRDM16 mutation: First description of a fetal presentation, with possible modifier genes

    by Geoffroy Delplancq, Georges Tarris, Antonio Vitobello, Sophie Nambot, Arthur Sorlin, Christophe Philippe, Virginie Carmignac, Yannis Duffourd, Charlotte Denis, Jean Christophe Eicher, et al.

    PRDM16 (positive regulatory domain 16) is localized in the critical region for cardiomyopathy in patients with deletions of chromosome 1p36, as defined by Gajecka et al., American Journal of Medical Genetics, 2010, 152A, 3074–3083, and encodes a zinc finger transcription factor. We present the first fetal case of left ventricular non‐compaction (LVNC) with a PRDM16 variant. The third‐trimester obstetric ultrasound revealed a hydropic fetus with hydramnios and expanded hypokinetic heart. After termination of pregnancy, foetopathology showed a eutrophic fetus with isolated cardiomegaly. Endocardial fibroelastosis was associated with non‐compaction of the myocardium of the left ventricle. Exome sequencing (ES) identified a de novo unreported p.(Gln353*) heterozygous nonsense variant in PRDM16. ES also identified two rare variants of unknown significance, according to the American College of Medical Genetics and Genomics guidelines, in the titin gene (TTN): a de novo missense p.(Lys14773Asn) variant and a c.33043+5A>G variant inherited from the mother. Along with the PRDM16 de novo probably pathogenic variant, TTN VOUS variants could possibly contribute to the severity and early onset of the cardiac phenotype. Because of the genetic heterogeneity of cardiomyopathies, large panels or even ES could be considered as the main approaches for the molecular diagnosis, particularly in fetal presentations, where multiple hits seem to be common.